Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.58 |
| ▸ | HTR2C | P28335 | 4/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | HTR2B | P41595 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | HTR1D | P28221 | 2/20 | 0.58 |
| ▸ | HTR1B | P28222 | 2/20 | 0.58 |
| ▸ | HTR7 | P34969 | 2/20 | 0.58 |
| ▸ | HTR6 | P50406 | 2/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.58 |
| ▸ | HTR3B | O95264 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.58 |
| ▸ | HTR1E | P28566 | 1/20 | 0.58 |
| ▸ | HTR1F | P30939 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28619891 | 0.98 | HTR2A (0.57) | HTR2AHTR2CHTR1AHTR2BCYP1A2 | |
| SCHEMBL25008689 | 0.83 | HTR2A (0.53) | HTR2AHTR2CHTR1AHTR2BCYP1A2 | |
| SCHEMBL21709093 | 0.81 | HTR2A (0.50) | HTR2AHTR2CHTR1AHTR2BCYP1A2 | |
| SCHEMBL1460642 | 0.75 | MPO (0.70) | HTR2AHTR2CHTR1AHTR2BCYP1A2 | |
| Serotonin SCHEMBL30057954 | 0.74 | HTR2C (1.00) | HTR2AHTR2CHTR1AHTR2BCYP1A2 | |
| Serotonin SCHEMBL1495 | 0.74 | HTR2C (1.00) | HTR2AHTR2CHTR1AHTR2BCYP1A2 | |
| Serotonin SCHEMBL29349412 | 0.74 | HTR2C (1.00) | HTR2AHTR2CHTR1AHTR2BCYP1A2 | |
| Serotonin SCHEMBL183226 | 0.74 | HTR2C (1.00) | HTR2AHTR2CHTR1AHTR2BCYP1A2 | |
| SCHEMBL1460686 | 0.74 | HTR2C (1.00) | HTR2AHTR2CHTR1AHTR2BCYP1A2 | |
| SCHEMBL15563081 | 0.74 | HTR2C (0.57) | HTR2AHTR2CHTR1AHTR2BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009124941-A2 | TRYPANOCIDAL COMPOUNDS TARGETED TO TRYPANOSOMES INTERIOR | AARHUS UNIVERSITET (DK) | 2009-10-15 | — | — | WO | claimed |
| EP-1776121-A2 | TREATMENT FOR METHAMPHETAMINE ADDICTION AND REDUCTION OF METHAMPHETAMINE USE USING SEROTONIN ANTAGONISTS | Omeros Corporation (US) | 2007-04-25 | — | — | EP | claimed |
| WO-2006017861-A2 | TREATMENT FOR METHAMPHETAMINE ADDICTION AND REDUCTION OF METHAMPHETAMINE USE USING SEROTONIN ANTAGONISTS | OMEROS CORPORATION (US) | 2006-02-16 | — | — | WO | claimed |
| US-20050160482-A1 | Assay for toxin induced neuronal degeneration and viability in C. elegans | VANDERBILT UNIVERSITY | 2005-07-21 | — | — | US | claimed |
| US-6894205-B2 | Assay for toxin induced neuronal degeneration and viability in C. elegans | VANDERBILT UNIVERSITY (US) | 2005-05-17 | — | — | US | claimed |
| US-20040097576-A1 | Use of tryptophan derivatives for the specific cytostatic treatment of serotonin-producing tumors | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2004-05-20 | — | — | US | claimed |
| EP-1368027-A2 | USE OF TRYPTOPHAN DERIVATIVES FOR THE SPECIFIC CYTOSTATIC TREATMENT OF SEROTONIN-PRODUCING TUMORS | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2003-12-10 | — | — | EP | claimed |
| US-20030023994-A1 | Assay for toxin induced neuronal degeneration and viability in C. elegans | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-30 | — | — | US | claimed |
| WO-2003001197-A1 | ASSAY FOR TOXIN INDUCED NEURONAL DEGENERATION AND VIABILITY IN C. ELEGANS | VANDERBILT UNIVERSITY (US) | 2003-01-03 | — | — | WO | claimed |
| WO-2002074309-A2 | USE OF TRYPTOPHAN DERIVATIVES FOR THE SPECIFIC CYTOSTATIC TREATMENT OF SEROTONIN-PRODUCING TUMORS | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2002-09-26 | — | — | WO | claimed |
| US-12226382-B2 | Methods for treating microglial dysfunction | WASHINGTON UNIVERSITY (US) | 2025-02-18 | — | — | US | disclosed |
| US-20240424005-A1 | DIAGNOSING, MONITORING AND TREATING NEUROLOGICAL DISEASE WITH PSYCHOACTIVE TRYPTAMINE DERIVATIVES AND mRNA MEASUREMENTS | LUDWIG ENTERPRISES, INC. | 2024-12-26 | — | — | US | disclosed |
| EP-3764992-B1 | PHARMACEUTICAL OR FOOD SUPPLEMENT PREPARATION BASED ON ALPHA-LACTALBUMIN | KOLFARMA S R L (IT) | 2024-08-14 | — | — | EP | disclosed |
| US-20240124404-A1 | COMPOSITION FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS COMPRISING INDOLE DERIVATIVE | METACEN THERAPEUTICS (KR) | 2024-04-18 | — | — | US | disclosed |
| EP-4353227-A1 | COMPOSITION INCLUDING INDOLE DERIVATIVE FOR PREVENTION OF ADVANCED GLYCATION END PRODUCT-RELATED DISEASE | Metacen Therapeutics (KR) | 2024-04-17 | — | — | EP | disclosed |
| EP-0441106-B1 | Thyroxine in restoring neuronal plasticity | GORIO ALFREDO (IT) | 1994-06-22 | — | — | EP | disclosed |
| US-5155129-A | For treating alzhimer*s disease by administering cyclopropachromen derivatives | SUNTORY LIMITED (JP) | 1992-10-13 | — | — | US | disclosed |
| WO-1992010200-A1 | FUNCTIONAL INTERACTIONS BETWEEN GLIAL S-100B AND CENTRAL NERVOUS SYSTEM SEROTONERGIC NEURONS | NEW YORK UNIVERSITY (US) | 1992-06-25 | — | — | WO | disclosed |
| US-5116873-A | Thyroid Hormone T4 | GORIO ALFREDO (IT) | 1992-05-26 | — | — | US | disclosed |
| EP-0441106-A2 | Thyroxine in restoring neuronal plasticity | Gorio, Alfredo (IT) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124404-A1 | COMPOSITION FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS COMPRISING INDOLE DERIVATIVE | AGER, IDO1, IAPP | HTR2A 339/4885HTR2C 611/4885HTR1A 524/4885 |
| US-12226382-B2 | Methods for treating microglial dysfunction | CHRNB2, PSEN2, CX3CR1 | HTR2A 468/4885HTR2C 1865/4885HTR1A 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.